Skip to main content
Back
Watch Compare

Perspective Therapeutics, Inc.

Data quality: 83%
CATX
NYSE Manufacturing Chemicals
$4.47
▲ $0.10 (2.29%)
Mkt Cap: 509.28 M
Price
$4.47
Mkt Cap
509.28 M
Day Range
$4.33 — $4.50
52-Week Range
$1.74 — $6.16
Volume
296,297
Open $4.36
50D / 200D Avg
$4.68
4.52% below
50D / 200D Avg
$3.58
24.80% above

Quick Summary

Key Takeaways

Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -95.23 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-40.61%
Above sector avg (-53.41%)
ROIC-31.37%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
0.01
Below sector avg (0.31)
Current Ratio8.66
Interest CoverageN/A

Valuation

PE (TTM)
-4.94
Below sector avg (-1.48)
P/B Ratio2.10
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -4.9 -1.5
P/B 2.1 1.6
ROE % -40.6 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E 0.0 0.3

ETFs Holding This Stock

BRSIX BRSIX
0.27% weight
GSSC logo GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF
0.01% weight
IRSSX IRSSX
0.01% weight
VVICX VVICX
0.01% weight
IRSIX IRSIX
0.01% weight
IIRSX IIRSX
0.01% weight
IRCIX IRCIX
0.01% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.00% weight
IWV logo IWV iShares Russell 3000 ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -103.12 M
ROE -40.61% ROA -34.06%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -95.23 M
ROIC -31.37% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 8.66
Interest Coverage N/A Asset Turnover N/A
Working Capital 157.88 M Tangible Book Value 242.22 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4.94 Forward P/E N/A
P/B Ratio 2.10 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -18.70%
Market Cap 509.28 M Enterprise Value 484.16 M
Per Share
EPS (Diluted TTM) -1.40 Revenue / Share N/A
FCF / Share -0.84 OCF / Share -0.72
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 92.35%
SBC-Adj. FCF -102.55 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — 2.51 M 2.71 M
Net Income -103.12 M -79.28 M -46.51 M -7.27 M -3.39 M
EPS (Diluted) -1.40 -1.23 — — —
Gross Profit — — 1.43 M 4.62 M 5.12 M
Operating Income -113.56 M -90.89 M -40.94 M -7.39 M -3.45 M
EBITDA — — — — —
R&D Expenses 84.22 M 41.64 M 21.31 M 2.58 M 1.43 M
SG&A Expenses — — — — —
D&A 3.25 M 2.31 M — — —
Interest Expense — — 84,000.0 — —
Income Tax -793,000.0 -2.10 M -2.65 M 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 266.97 M 341.10 M 97.89 M 64.44 M 70.42 M
Total Liabilities 59.94 M 50.43 M 22.71 M 3.16 M 3.01 M
Shareholders' Equity 207.03 M 290.67 M 75.18 M 61.28 M 67.41 M
Total Debt 1.63 M 1.68 M 1.73 M — —
Cash & Equivalents 30.63 M 61.58 M 9.24 M 55.89 M 63.83 M
Current Assets 148.39 M 231.16 M 16.84 M 59.33 M 67.30 M
Current Liabilities 28.68 M 18.23 M 15.66 M 2.27 M 1.80 M